Posts tagged ‘non-melanoma skin cancer’
August 3rd, 2011
At ASCO this year, there was a lot of interest in BRAF mutated melanoma, with data being presented in the plenary session on vemurafenib (PLX4032) and ipilimumab.
However, as Sally Church on Pharma Strategy Blog points out, 40% of all new cancer cases are due to non-melanoma skin cancer, with over one million diagnoses each year in the US.
Sally discusses research published in the AACR journal Cancer Research by Mei Ming and colleagues from the University of Chicago on how the tumor suppressor gene phosphatase and tensin homolog deleted from chromosome ten (PTEN) regulates UVB-induced DNA damage.
The research shows that PTEN has a key role to play in human skin cancer formation and progression with low levels of PTEN associated with slower rates of DNA repair after UVB radiation damage.
As Sally notes on her blog, “a greater understanding of the molecular mechanisms underpinning non-melanoma skin cancer potentially means that chemoprevention strategies can be developed down the road.”
You can read more about the role PTEN plays in non-melanoma skin cancer on Pharma Strategy Blog.